Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:AVDL NASDAQ:AXSM NASDAQ:NUVL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$81.03-0.7%$44.05$4.77▼$82.13$6.12B0.561.10 million shs578,505 shsAVDLAvadel Pharmaceuticals$14.76+1.0%$11.44$6.38▼$16.66$1.43B1.471.34 million shs1.65 million shsAXSMAxsome Therapeutics$121.28-0.4%$108.21$75.56▼$139.13$6.05B0.51586,635 shs351,676 shsNUVLNuvalent$76.58+0.7%$78.54$55.53▼$113.51$5.52B1.3433,328 shs418,360 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax0.00%+4.85%+12.90%+1,250.50%+560.93%AVDLAvadel Pharmaceuticals0.00%-3.15%+40.44%+61.66%-0.67%AXSMAxsome Therapeutics0.00%+2.34%+19.63%+15.59%+37.15%NUVLNuvalent0.00%+0.66%-2.26%+4.01%-9.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVXAbivax2.5919 of 5 stars3.63.00.00.02.90.80.6AVDLAvadel Pharmaceuticals2.9885 of 5 stars3.63.00.00.03.51.70.6AXSMAxsome Therapeutics4.7883 of 5 stars4.51.00.04.54.04.20.6NUVLNuvalent3.3728 of 5 stars4.51.00.00.03.73.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 3.13Buy$92.3313.95% UpsideAVDLAvadel Pharmaceuticals 3.14Buy$19.6733.24% UpsideAXSMAxsome Therapeutics 3.07Buy$178.0046.77% UpsideNUVLNuvalent 3.09Buy$120.8057.74% UpsideCurrent Analyst Ratings BreakdownLatest AVDL, AXSM, ABVX, and NUVL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025AVDLAvadel PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $20.008/19/2025NUVLNuvalentPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$112.008/8/2025AVDLAvadel PharmaceuticalsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/8/2025AVDLAvadel PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/8/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $24.008/5/2025AXSMAxsome TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$173.00 ➝ $176.008/5/2025AXSMAxsome TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$184.00 ➝ $189.008/4/2025AXSMAxsome TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$150.007/29/2025ABVXAbivaxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$70.00 ➝ $112.007/23/2025ABVXAbivaxLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$74.007/23/2025ABVXAbivaxLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$45.00 ➝ $101.00(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$0.69 per shareN/AAVDLAvadel Pharmaceuticals$169.12M8.47N/AN/A$0.93 per share15.87AXSMAxsome Therapeutics$495.03M12.23N/AN/A$1.46 per share83.07NUVLNuvalentN/AN/AN/AN/A$13.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$190.71MN/A0.00N/AN/AN/AN/AN/AN/AAVDLAvadel Pharmaceuticals-$48.83M-$0.03N/A246.00N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)AXSMAxsome Therapeutics-$287.22M-$5.07N/A43.01N/A-49.88%-283.22%-33.06%11/11/2025 (Estimated)NUVLNuvalent-$260.76M-$4.90N/AN/AN/AN/A-32.58%-30.14%11/11/2025 (Estimated)Latest AVDL, AXSM, ABVX, and NUVL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02$0.10+$0.08$0.10$60.28 million$68.13 million8/7/2025Q2 2025NUVLNuvalent-$1.27-$1.31-$0.04-$1.39N/AN/A8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivax1.291.251.25AVDLAvadel PharmaceuticalsN/A2.792.38AXSMAxsome Therapeutics1.661.571.51NUVLNuvalentN/A13.5713.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%AVDLAvadel Pharmaceuticals69.19%AXSMAxsome Therapeutics81.49%NUVLNuvalent97.26%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/AAVDLAvadel Pharmaceuticals5.20%AXSMAxsome Therapeutics22.30%NUVLNuvalent10.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6175.57 millionN/ANot OptionableAVDLAvadel Pharmaceuticals7097.10 million92.05 millionOptionableAXSMAxsome Therapeutics38049.90 million38.77 millionOptionableNUVLNuvalent4072.11 million64.75 millionOptionableAVDL, AXSM, ABVX, and NUVL HeadlinesRecent News About These CompaniesDriehaus Capital Management LLC Has $37.67 Million Stock Position in Nuvalent, Inc. $NUVLAugust 31 at 7:14 AM | marketbeat.comNuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of "Buy" from AnalystsAugust 31 at 2:11 AM | marketbeat.comNuvalent, Inc. $NUVL Shares Bought by Tema Etfs LLCAugust 30 at 8:19 AM | marketbeat.comTri Locum Partners LP Makes New $6.80 Million Investment in Nuvalent, Inc. $NUVLAugust 30 at 8:04 AM | marketbeat.comNuvalent, Inc. $NUVL Shares Sold by Jump Financial LLCAugust 30 at 5:00 AM | marketbeat.comNuvalent, Inc. $NUVL Holdings Raised by Affinity Asset Advisors LLCAugust 28 at 9:02 AM | marketbeat.comNuvalent to Participate in the Cantor Global Healthcare Conference 2025August 28 at 6:30 AM | prnewswire.comPrice T Rowe Associates Inc. MD Raises Stock Position in Nuvalent, Inc. $NUVLAugust 28 at 4:52 AM | marketbeat.comNuveen LLC Buys Shares of 83,976 Nuvalent, Inc. $NUVLAugust 28 at 3:36 AM | marketbeat.comT. Rowe Price Investment Management Inc. Makes New $31.97 Million Investment in Nuvalent, Inc. $NUVLAugust 26, 2025 | marketbeat.comNuvalent, Inc. $NUVL Shares Purchased by American Century Companies Inc.August 26, 2025 | marketbeat.comNuvalent, Inc. $NUVL Shares Purchased by Wellington Management Group LLPAugust 24, 2025 | marketbeat.comNuvalent, Inc. $NUVL Shares Sold by Deutsche Bank AGAugust 24, 2025 | marketbeat.comNuvalent, Inc. $NUVL Shares Sold by Charles Schwab Investment Management Inc.August 24, 2025 | marketbeat.comCandriam S.C.A. Sells 13,966 Shares of Nuvalent, Inc. $NUVLAugust 23, 2025 | marketbeat.comAberdeen Group plc Acquires 19,987 Shares of Nuvalent, Inc. $NUVLAugust 23, 2025 | marketbeat.comNuvalent, Inc. $NUVL Shares Purchased by Russell Investments Group Ltd.August 22, 2025 | marketbeat.comNuvalent (NASDAQ:NUVL) CEO Sells $2,036,340.00 in StockAugust 21, 2025 | marketbeat.comNuvalent (NASDAQ:NUVL) Now Covered by Piper SandlerAugust 21, 2025 | marketbeat.comInsider Selling: Nuvalent (NASDAQ:NUVL) CEO Sells 27,000 Shares of StockAugust 20, 2025 | insidertrades.comPiper Sandler Initiates Coverage on Nuvalent (NASDAQ:NUVL)August 20, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVDL, AXSM, ABVX, and NUVL Company DescriptionsAbivax NASDAQ:ABVX$81.03 -0.61 (-0.75%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$81.39 +0.36 (+0.44%) As of 08/29/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Avadel Pharmaceuticals NASDAQ:AVDL$14.76 +0.14 (+0.96%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$15.05 +0.29 (+1.99%) As of 08/29/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Axsome Therapeutics NASDAQ:AXSM$121.28 -0.47 (-0.39%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$121.25 -0.03 (-0.02%) As of 08/29/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Nuvalent NASDAQ:NUVL$76.58 +0.56 (+0.74%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$76.60 +0.02 (+0.02%) As of 08/29/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
